The goal of this proposal is to evaluate the transplantation of positively selected autologous hematopoietic stem cells (HSC) in pediatric patients with acute lymphoblastic leukemia (ALL). Previous results with autologous HSC transplantation (HSCT) for ALL have reported an unacceptable high relapse rates possibly due to leukemia cells contaminating the transplanted HSC. HSC will be positively selected by fluorescence activated cell sorting (FACS) based upon immunophenotypic differences between HSC (CD34+, CD38-, yc-) and ALL cells (CD34+, CD38+, yc+). Positively selected HSC will be evaluated 1) for their hematopoietic potential and 2) the presence of residual leukemia cells by PCR analysis for leukemia specific clonotypic TCR-6 rearrangements. PCR analysis of the clonospecific TCR-6 rearrangement permits an independent assessment of the purity of the isolated HSC (Specific Aim 1). All patients will be prepared for HSCT with total body irradiation and VP-16, and their rate of lymphohematopoietic reconstitution determined following the transplantation of the positively selected HSC (Specific Aim 2). After the demonstration that positively selected HSC can engraft in a clinically relevant time frame, an aliquot of the isolated HSC will be transduced with a glucocerebrosidase (GC) containing lentivirus based vector prior to cryopreservation. Both the transduced and non-transduced HSC will then be transplanted. Lentivirus based vectors will be used since our previous work has shown that murine leukemia based vectors poorly transduced quiescent HSC. Using inverse PCR techniques the clonality and the multi- lineage progeny of the transduced HSC will be longitudinally assessed. If patients relapse, their relapsed leukemia cells will be isolated and assess for the presence of the transduced vector to determine if the transplanted HSC contributed to relapse (Specific Aim 3). Overall this grant is an attempt to demonstrate that the transplantation of positively selected HSC (Cb34+, CD38-, yc-) can successfully lymphohematopoietic reconstitute pediatric ALL patients and that lentivirus vectors can transduce pluripotent HSC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA059318-07A2
Application #
6475002
Study Section
Project Start
1992-09-30
Project End
2006-06-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
7
Fiscal Year
2001
Total Cost
$184,121
Indirect Cost
Name
University of Southern California
Department
Type
DUNS #
041544081
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Perez, Omar D; Logg, Christopher R; Hiraoka, Kei et al. (2012) Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression. Mol Ther 20:1689-98
Christodoulopoulos, Ilias; Droniou-Bonzom, Magali E; Oldenburg, Jill E et al. (2010) Vpu-dependent block to incorporation of GaLV Env into lentiviral vectors. Retrovirology 7:4
Epand, Raquel F; Zhang, Yan-Liang; Mirzabekov, Tajib et al. (2008) Membrane activity of an amphiphilic alpha-helical membrane-proximal cytoplasmic domain of the MoMuLV envelope glycoprotein. Exp Mol Pathol 84:9-17
Rozenberg-Adler, Yanina; Conner, John; Aguilar-Carreno, Hector et al. (2008) Membrane-proximal cytoplasmic domain of Moloney murine leukemia virus envelope tail facilitates fusion. Exp Mol Pathol 84:18-30
Logg, Christopher R; Baranick, Brian T; Lemp, Nathan A et al. (2007) Adaptive evolution of a tagged chimeric gammaretrovirus: identification of novel cis-acting elements that modulate splicing. J Mol Biol 369:1214-29
Hiraoka, Kei; Kimura, Takahiro; Logg, Christopher R et al. (2007) Therapeutic efficacy of replication-competent retrovirus vector-mediated suicide gene therapy in a multifocal colorectal cancer metastasis model. Cancer Res 67:5345-53
Weber, Erin L; Cannon, Paula M (2007) Promoter choice for retroviral vectors: transcriptional strength versus trans-activation potential. Hum Gene Ther 18:849-60
Kikuchi, Eiji; Menendez, Silvia; Ozu, Choichiro et al. (2007) Highly efficient gene delivery for bladder cancers by intravesically administered replication-competent retroviral vectors. Clin Cancer Res 13:4511-8
Hsu, Faye Yuan-yi; Zhao, Yi; Anderson, W French et al. (2007) Downregulation of NPM-ALK by siRNA causes anaplastic large cell lymphoma cell growth inhibition and augments the anti cancer effects of chemotherapy in vitro. Cancer Invest 25:240-8
Kikuchi, E; Menendez, S; Ozu, C et al. (2007) Delivery of replication-competent retrovirus expressing Escherichia coli purine nucleoside phosphorylase increases the metabolism of the prodrug, fludarabine phosphate and suppresses the growth of bladder tumor xenografts. Cancer Gene Ther 14:279-86

Showing the most recent 10 out of 70 publications